

Please amend the claims in accordance with the following Listing of Claims, which replaces all previous Listings of Claims in this case.

Listing of Claims

1. (Currently amended) A method for treating a subject for a condition mediated by eotaxin which comprises generating an active immune response in the subject to human eotaxin, wherein the condition mediated by eotaxin is selected from asthma, allergy or allergic disease and wherein the subject is a human.
2. (Currently amended) The method of claim 1 wherein the condition mediated by eotaxin is ~~asthma, allergy or allergic disease.~~
3. (Currently amended) The method of claim 1 wherein the active immune response comprises generating autoantibodies in the subject which bind to human eotaxin at a level sufficient to neutralize the effect of eotaxin in mediating the condition.
4. (Currently amended) The method of claim 1, which comprises immunizing the subject with an immunogenic composition, which generates antibodies in the subject, which bind to human eotaxin.
5. (Original) The method of claim 4 wherein the immunogenic composition comprises eotaxin or a portion of eotaxin bound to an immunogenic carrier.
6. (Withdrawn) The method of claim 5 wherein the immunogenic carrier comprises a T-cell epitope and an eotaxin derived epitope.
7. (Withdrawn) The method of claim 6 wherein the immunogenic composition comprises an

immunogenic analog of the eotaxin.

8. (Withdrawn) The method of claim 4 wherein the immunogenic composition is a DNA vaccine.
9. (Withdrawn) An immunogenic composition comprising eotaxin or a peptide fragment thereof coupled to an immunogenic protein carrier.
10. (Withdrawn) The immunogenic composition of claim 9 comprising a T-cell epitope and an epitope derived from eotaxin.
11. (Withdrawn) The immunogenic composition of claim 9 comprising eotaxin or a portion thereof conjugated to an immunogenic carrier derived from DT, TT or KLH.
12. (Withdrawn) A method of producing the composition of claim 9 or 11, which comprises conjugating the eotaxin or a portion thereof to the immunogenic carrier.
13. (Withdrawn) A pharmaceutical formulation for use as a therapeutic vaccine comprising the immunogenic composition of claim 9, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable vehicle.
14. (Withdrawn) The immunogenic composition of claim 9 comprising a peptide sequence selected from the peptide sequences set forth in SEQ ID Nos. 1-38 and 42-61 or mixtures thereof.
15. (Withdrawn) A DNA vaccine that encodes a peptide, which generates an immune response to eotaxin.